---
document_datetime: 2025-12-02 05:08:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/menquadfi.html
document_name: menquadfi.html
version: success
processing_time: 0.1199005
conversion_datetime: 2025-12-24 23:12:35.209987
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# MenQuadfi

[RSS](/en/individual-human-medicine.xml/67366)

##### Authorised

This medicine is authorised for use in the European Union

meningococcal group A, C, W-135 and Y conjugate vaccine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on MenQuadfi](#news-on)
- [More information on MenQuadfi](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

MenQuadfi is a vaccine used to protect adults and children from the age of 12 months against invasive meningococcal disease caused by four groups of the *Neisseria meningitidis* bacteria (group A, C, W, and Y). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood poisoning).

The vaccine contains substances from the outer coat of *N. meningitidis* bacteria.

Expand section

Collapse section

## How is MenQuadfi used?

MenQuadfi is given as a single injection into the shoulder muscle or on the side of the thigh. Some people can be given a booster dose.

MenQuadfi can only be obtained with a prescription and should be used according to available official recommendations. For more information about using MenQuadfi, see the package leaflet or contact your doctor or pharmacist.

## How does MenQuadfi work?

MenQuadfi is a vaccine. Vaccines work by preparing the immune system (the body's natural defences) to defend the body against a specific disease.

MenQuadfi contains small amounts of sugars from the outer coat of four groups of the *N. meningitidis* bacteria: A, C, W and Y. When a person is given the vaccine, the immune system recognises the sugars as 'foreign' and makes antibodies against them. If the person later comes into contact with the bacteria, these antibodies, together with other components of the immune system, will be able to fight off the bacteria more effectively and so help protect the person against the disease.

## What benefits of MenQuadfi have been shown in studies?

The ability of MenQuadfi to trigger the production of antibodies (immunogenicity) was assessed in seven main studies involving over 9,000 participants aged 1 year or older. MenQuadfi was compared with several other similar vaccines against *N. meningitidis* . Results showed that a single injection of MenQuadfi was as effective as the other vaccines in stimulating the body to produce antibodies that would protect against the four types of *N. meningitidis* .

## What are the risks associated with MenQuadfi?

The most common side effects with MenQuadfi (which may affect more than 1 in 10 people) are headache, muscle pain, malaise (feeling unwell) and pain at the site of injection. For the full list of side effects and restrictions of MenQuadfi, see the package leaflet.

## Why is MenQuadfi authorised in the EU?

MenQuadfi had been shown to be at least as effective as similar vaccines at stimulating an immune response to the four groups of the *N. meningitidis* bacteria in people of different age groups. Furthermore, MenQuadfi is well tolerated and there were no reports of serious or unexpected side effects. The European Medicines Agency therefore decided that MenQuadfi's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of MenQuadfi?

The company that markets MenQuadfi will complete studies to assess the effects of a second dose of the vaccine (a booster) after previous vaccination with MenQuadfi or a similar vaccine.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of MenQuadfi have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of MenQuadfi are continuously monitored. Side effects reported with MenQuadfi are carefully evaluated and any necessary action taken to protect patients.

## Other information about MenQuadfi

MenQuadfi received a marketing authorisation valid throughout the EU on 18.11.2020.

MenQuadfi : EPAR - Medicine overview

Reference Number: EMA/537720/2020

English (EN) (123.1 KB - PDF)

**First published:** 27/11/2020

[View](/en/documents/overview/menquadfi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-377)

български (BG) (144.36 KB - PDF)

**First published:**

27/11/2020

[View](/bg/documents/overview/menquadfi-epar-medicine-overview_bg.pdf)

español (ES) (113.47 KB - PDF)

**First published:**

27/11/2020

[View](/es/documents/overview/menquadfi-epar-medicine-overview_es.pdf)

čeština (CS) (143.42 KB - PDF)

**First published:**

27/11/2020

[View](/cs/documents/overview/menquadfi-epar-medicine-overview_cs.pdf)

dansk (DA) (112.5 KB - PDF)

**First published:**

27/11/2020

[View](/da/documents/overview/menquadfi-epar-medicine-overview_da.pdf)

Deutsch (DE) (115.65 KB - PDF)

**First published:**

27/11/2020

[View](/de/documents/overview/menquadfi-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.65 KB - PDF)

**First published:**

27/11/2020

[View](/et/documents/overview/menquadfi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (143.87 KB - PDF)

**First published:**

27/11/2020

[View](/el/documents/overview/menquadfi-epar-medicine-overview_el.pdf)

français (FR) (80.16 KB - PDF)

**First published:**

27/11/2020

[View](/fr/documents/overview/menquadfi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (133.45 KB - PDF)

**First published:**

27/11/2020

[View](/hr/documents/overview/menquadfi-epar-medicine-overview_hr.pdf)

italiano (IT) (111.36 KB - PDF)

**First published:**

27/11/2020

[View](/it/documents/overview/menquadfi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (152.3 KB - PDF)

**First published:**

27/11/2020

[View](/lv/documents/overview/menquadfi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (141.38 KB - PDF)

**First published:**

27/11/2020

[View](/lt/documents/overview/menquadfi-epar-medicine-overview_lt.pdf)

magyar (HU) (133.33 KB - PDF)

**First published:**

27/11/2020

[View](/hu/documents/overview/menquadfi-epar-medicine-overview_hu.pdf)

Malti (MT) (142.74 KB - PDF)

**First published:**

27/11/2020

[View](/mt/documents/overview/menquadfi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (112.86 KB - PDF)

**First published:**

27/11/2020

[View](/nl/documents/overview/menquadfi-epar-medicine-overview_nl.pdf)

polski (PL) (135.86 KB - PDF)

**First published:**

27/11/2020

[View](/pl/documents/overview/menquadfi-epar-medicine-overview_pl.pdf)

português (PT) (113.1 KB - PDF)

**First published:**

27/11/2020

[View](/pt/documents/overview/menquadfi-epar-medicine-overview_pt.pdf)

română (RO) (140.54 KB - PDF)

**First published:**

27/11/2020

[View](/ro/documents/overview/menquadfi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (143.49 KB - PDF)

**First published:**

27/11/2020

[View](/sk/documents/overview/menquadfi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (132.31 KB - PDF)

**First published:**

27/11/2020

[View](/sl/documents/overview/menquadfi-epar-medicine-overview_sl.pdf)

Suomi (FI) (110.89 KB - PDF)

**First published:**

27/11/2020

[View](/fi/documents/overview/menquadfi-epar-medicine-overview_fi.pdf)

svenska (SV) (112.38 KB - PDF)

**First published:**

27/11/2020

[View](/sv/documents/overview/menquadfi-epar-medicine-overview_sv.pdf)

MenQuadfi : EPAR - Risk management plan

English (EN) (791.49 KB - PDF)

**First published:** 27/11/2020

**Last updated:** 18/04/2024

[View](/en/documents/rmp/menquadfi-epar-risk-management-plan_en.pdf)

## Product information

MenQuadfi : EPAR - Product information

English (EN) (467.98 KB - PDF)

**First published:** 27/11/2020

**Last updated:** 04/07/2025

[View](/en/documents/product-information/menquadfi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-220)

български (BG) (762.99 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/bg/documents/product-information/menquadfi-epar-product-information_bg.pdf)

español (ES) (804.17 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/es/documents/product-information/menquadfi-epar-product-information_es.pdf)

čeština (CS) (1.07 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/cs/documents/product-information/menquadfi-epar-product-information_cs.pdf)

dansk (DA) (673.03 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/da/documents/product-information/menquadfi-epar-product-information_da.pdf)

Deutsch (DE) (726.67 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/de/documents/product-information/menquadfi-epar-product-information_de.pdf)

eesti keel (ET) (603.96 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/et/documents/product-information/menquadfi-epar-product-information_et.pdf)

ελληνικά (EL) (781.67 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/el/documents/product-information/menquadfi-epar-product-information_el.pdf)

français (FR) (738.5 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/fr/documents/product-information/menquadfi-epar-product-information_fr.pdf)

hrvatski (HR) (564.27 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/hr/documents/product-information/menquadfi-epar-product-information_hr.pdf)

íslenska (IS) (653.63 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/is/documents/product-information/menquadfi-epar-product-information_is.pdf)

italiano (IT) (776.61 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/it/documents/product-information/menquadfi-epar-product-information_it.pdf)

latviešu valoda (LV) (673.99 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/lv/documents/product-information/menquadfi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (777.96 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/lt/documents/product-information/menquadfi-epar-product-information_lt.pdf)

magyar (HU) (795.18 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/hu/documents/product-information/menquadfi-epar-product-information_hu.pdf)

Malti (MT) (845.81 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/mt/documents/product-information/menquadfi-epar-product-information_mt.pdf)

Nederlands (NL) (704.09 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/nl/documents/product-information/menquadfi-epar-product-information_nl.pdf)

norsk (NO) (811.68 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/no/documents/product-information/menquadfi-epar-product-information_no.pdf)

polski (PL) (785.89 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/pl/documents/product-information/menquadfi-epar-product-information_pl.pdf)

português (PT) (1007.83 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/pt/documents/product-information/menquadfi-epar-product-information_pt.pdf)

română (RO) (659.3 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/ro/documents/product-information/menquadfi-epar-product-information_ro.pdf)

slovenčina (SK) (644.12 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/sk/documents/product-information/menquadfi-epar-product-information_sk.pdf)

slovenščina (SL) (811.62 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/sl/documents/product-information/menquadfi-epar-product-information_sl.pdf)

Suomi (FI) (1.17 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/fi/documents/product-information/menquadfi-epar-product-information_fi.pdf)

svenska (SV) (1.02 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

04/07/2025

[View](/sv/documents/product-information/menquadfi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000245024 02/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

MenQuadfi : EPAR - All authorised presentations

English (EN) (53.59 KB - PDF)

**First published:** 27/11/2020

**Last updated:** 19/05/2022

[View](/en/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-324)

български (BG) (63.17 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/bg/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.29 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/es/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (58.84 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/cs/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (120.54 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/da/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (53.65 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/de/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (26.17 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/et/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (74.06 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/el/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_el.pdf)

français (FR) (69.35 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/fr/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (49.99 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/hr/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (54.21 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/is/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (68.05 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/it/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (83.27 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/lv/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (82.66 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/lt/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (40.41 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/hu/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (103.6 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/mt/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (42.4 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/nl/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (62.53 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/no/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_no.pdf)

polski (PL) (82.92 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/pl/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_pl.pdf)

português (PT) (62.3 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/pt/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_pt.pdf)

română (RO) (68.63 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/ro/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (77.74 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/sk/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (49.1 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/sl/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (45.38 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/fi/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.63 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

19/05/2022

[View](/sv/documents/all-authorised-presentations/menquadfi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine MenQuadfi Active substance

- Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid
- Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid
- Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid
- Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid

International non-proprietary name (INN) or common name meningococcal group A, C, W-135 and Y conjugate vaccine Therapeutic area (MeSH) Meningitis, Meningococcal Anatomical therapeutic chemical (ATC) code J07AH08

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.

The use of this vaccine should be in accordance with available official recommendations.

## Authorisation details

EMA product number EMEA/H/C/005084 Marketing authorisation holder

Sanofi Winthrop Industrie

82 Avenue Raspail

Opinion adopted 17/09/2020 Marketing authorisation issued 18/11/2020 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

MenQuadfi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (150.06 KB - PDF)

**First published:** 03/03/2025

**Last updated:** 04/07/2025

[View](/en/documents/procedural-steps-after/menquadfi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

MenQuadfi : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (296.64 KB - PDF)

**First published:** 19/04/2021

**Last updated:** 03/03/2025

[View](/en/documents/procedural-steps-after/menquadfi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

MenQuadfi-PAM/0000291488 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2353917

English (EN) (3.14 MB - PDF)

**First published:** 28/11/2025

[View](/en/documents/variation-report/menquadfi-pam-0000291488-epar-assessment-report_en.pdf)

MenQuadfi-PAM-0000293240 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2383013

English (EN) (1.24 MB - PDF)

**First published:** 28/11/2025

[View](/en/documents/variation-report/menquadfi-pam-0000293240-epar-assessment-report_en.pdf)

MenQuadfi-PAM-0000293638 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2390991

English (EN) (2.09 MB - PDF)

**First published:** 28/11/2025

[View](/en/documents/variation-report/menquadfi-pam-0000293638-epar-assessment-report_en.pdf)

MenQuadfi-PAM-0000250392 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-1902820

English (EN) (2.16 MB - PDF)

**First published:** 11/06/2025

[View](/en/documents/variation-report/menquadfi-pam-0000250392-epar-assessment-report_en.pdf)

MenQuadfi H/C/005084/P46/013 - Assessment report

Adopted

Reference Number: EMA/466192/2024

English (EN) (2.93 MB - PDF)

**First published:** 16/10/2024

[View](/en/documents/variation-report/menquadfi-h-c-005084-p46-013-assessment-report_en.pdf)

MenQuadfi H/C/005084/P46/012 - Assessment report

Adopted

Reference Number: EMA/308452/2024

English (EN) (3.56 MB - PDF)

**First published:** 30/07/2024

[View](/en/documents/variation-report/menquadfi-h-c-005084-p46-012-assessment-report_en.pdf)

MenQuadfi-H-C-005084-P46-007 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/146989/2024

English (EN) (4.28 MB - PDF)

**First published:** 03/05/2024

[View](/en/documents/variation-report/menquadfi-h-c-005084-p46-007-epar-assessment-report_en.pdf)

MenQuadfi-H-C-005084-P46-009 : EPAR - Assessment report

Adopted

Reference Number: EMA/59046/2024

English (EN) (5.53 MB - PDF)

**First published:** 08/02/2024

[View](/en/documents/variation-report/menquadfi-h-c-005084-p46-009-epar-assessment-report_en.pdf)

MenQuadfi-H-C-005084-P46-008 : EPAR - Assessment report

Adopted

Reference Number: EMA/59102/2024

English (EN) (4.07 MB - PDF)

**First published:** 08/02/2024

[View](/en/documents/variation-report/menquadfi-h-c-005084-p46-008-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

MenQuadfi : EPAR - Public assessment report

Adopted

Reference Number: EMA/522942/2020

English (EN) (3.5 MB - PDF)

**First published:** 27/11/2020

[View](/en/documents/assessment-report/menquadfi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for MenQuadfi

Adopted

Reference Number: EMA/CHMP/452678/2020

English (EN) (142.91 KB - PDF)

**First published:** 18/09/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-menquadfi_en.pdf)

#### News on MenQuadfi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020) 18/09/2020

#### More information on MenQuadfi

- [EMEA-001930-PIP01-16-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001930-pip01-16-m06)
- [The MenQuadfi™ Pregnancy Registry: A surveillance registry to assess the safety of MenQuadfi™ among exposed pregnant women and their offspring (MEQ00070) - post-authorisation study](https://catalogues.ema.europa.eu/study/38094)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Vaccines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A76)

**This page was last updated on** 28/11/2025

## Share this page

[Back to top](#main-content)